- Home
- CIGL vs SNTI Comparison
CIGL vs SNTI Comparison
Compare CIGL & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- SNTI
- Stock Information
- Founded
- CIGL 1997
- SNTI 2016
- Country
- CIGL Singapore
- SNTI United States
- Employees
- CIGL N/A
- SNTI N/A
- Industry
- CIGL Diversified Commercial Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- CIGL Consumer Discretionary
- SNTI Health Care
- Exchange
- CIGL Nasdaq
- SNTI Nasdaq
- Market Cap
- CIGL 57.6M
- SNTI 53.6M
- IPO Year
- CIGL 2025
- SNTI N/A
- Fundamental
- Price
- CIGL $2.54
- SNTI $1.94
- Analyst Decision
- CIGL
- SNTI Strong Buy
- Analyst Count
- CIGL 0
- SNTI 3
- Target Price
- CIGL N/A
- SNTI $9.67
- AVG Volume (30 Days)
- CIGL 33.2K
- SNTI 286.1K
- Earning Date
- CIGL 09-29-2025
- SNTI 11-12-2025
- Dividend Yield
- CIGL N/A
- SNTI N/A
- EPS Growth
- CIGL N/A
- SNTI N/A
- EPS
- CIGL N/A
- SNTI N/A
- Revenue
- CIGL $11,072,733.00
- SNTI N/A
- Revenue This Year
- CIGL N/A
- SNTI N/A
- Revenue Next Year
- CIGL N/A
- SNTI $150.00
- P/E Ratio
- CIGL N/A
- SNTI N/A
- Revenue Growth
- CIGL 6.32
- SNTI N/A
- 52 Week Low
- CIGL $1.40
- SNTI $1.26
- 52 Week High
- CIGL $31.06
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- SNTI 50.78
- Support Level
- CIGL N/A
- SNTI $1.80
- Resistance Level
- CIGL N/A
- SNTI $2.29
- Average True Range (ATR)
- CIGL 0.00
- SNTI 0.15
- MACD
- CIGL 0.00
- SNTI -0.04
- Stochastic Oscillator
- CIGL 0.00
- SNTI 28.57
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.